{"id":3998,"date":"2017-08-13T07:38:59","date_gmt":"2017-08-13T07:38:59","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/andromedic-esho-2014\/"},"modified":"2026-02-17T10:20:31","modified_gmt":"2026-02-17T10:20:31","slug":"andromedic-esho-2014","status":"publish","type":"page","link":"https:\/\/andromedichyperthermia.com\/no\/andromedic-esho-2014\/","title":{"rendered":"Andromedic intervensjon ESHO 2014"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"MedicalWebPage\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/no\/andromedic-esho-2014\/#webpage\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/no\/andromedic-esho-2014\/\",\n      \"name\": \"Kliniske studier med Andromedic HyDeep 600 WM - ESHO-kongressen\",\n      \"description\": \"Data fra kliniske studier med HyDeep 600 WM for livmorhalskreft og multisenter mulighetsstudier presentert ved ESHO-kongressen.\",\n      \"inLanguage\": \"nb-NO\",\n      \"isPartOf\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#website\" },\n      \"mainEntity\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\" },\n      \"about\": [\n        {\n          \"@type\": \"MedicalStudy\",\n          \"name\": \"LACC Livmorhalskreft-studie\",\n          \"description\": \"Studie p\u00e5 8 pasienter som viser 100 % lokal kontroll ved bruk av HyDeep 600 WM og HDR-brakyterapi.\",\n          \"studySubject\": { \"@type\": \"MedicalCondition\", \"name\": \"Livmorhalskreft\" }\n        },\n        {\n          \"@type\": \"MedicalStudy\",\n          \"name\": \"Spansk case-control studie\",\n          \"description\": \"Omfattende mulighetsstudie (feasibility study) med 293 pasienter fordelt p\u00e5 9 tumorsteder.\",\n          \"sampleSize\": 293,\n          \"studyStatus\": \"Published\"\n        }\n      ],\n      \"mentions\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/hyperthermia-doctor-salvatore-conte\/\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" }\n      ]\n    },\n    {\n      \"@type\": [\"Product\", \"MedicalDevice\"],\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\",\n      \"name\": \"HyDeep 600WM\",\n      \"brand\": { \"@type\": \"Brand\", \"name\": \"Andromedic\" },\n      \"image\": \"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/HyDeep-600WM-Andromedic.jpg\",\n      \"description\": \"Avansert onkologisk hypertermisystem \/ profesjonelt utstyr for modulert RF-hypertermi (13,56 MHz) for lokal dyp hypertermi.\",\n      \"offers\": {\n        \"@type\": \"Offer\",\n        \"price\": \"0\",\n        \"priceCurrency\": \"EUR\",\n        \"availability\": \"https:\/\/schema.org\/InStock\",\n        \"url\": \"https:\/\/andromedichyperthermia.com\/no\/contact\/\",\n        \"priceSpecification\": {\n          \"@type\": \"PriceSpecification\",\n          \"description\": \"Pris p\u00e5 foresp\u00f8rsel\"\n        }\n      },\n      \"review\": {\n        \"@type\": \"Review\",\n        \"author\": { \"@type\": \"Person\", \"name\": \"Dr. med. Veronica Iatan\" },\n        \"reviewRating\": { \"@type\": \"Rating\", \"ratingValue\": \"5\", \"bestRating\": \"5\" },\n        \"reviewBody\": \"Ledende teknologi for dyp hypertermi med klinisk validerte protokoller.\"\n      }\n    },\n    {\n      \"@type\": \"MedicalOrganization\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\",\n      \"name\": \"Andromedic Srl\"\n    }\n  ]\n}\n<\/script><\/p>\n<div style=\"line-height: 1.6; color: #333; max-width: 1100px; margin: auto; font-family: 'Segoe UI', Helvetica, sans-serif; background-color: #fff; padding: 20px;\">\n<header style=\"border-bottom: 4px solid #1a2a6c; padding-bottom: 25px; margin-bottom: 40px; text-align: center;\">\n<h1 style=\"color: #1a2a6c; font-size: 28px; font-weight: 800; text-transform: uppercase; margin-bottom: 10px;\">European Society for Hyperthermic Oncology: ESHO 2014<\/h1>\n<h2 style=\"color: #b21f1f; font-size: 20px; font-weight: 600;\">Andromedic-intervensjon \u2013 Dr. Salvatore Conte<\/h2>\n<p style=\"font-size: 16px; max-width: 850px; margin: 15px auto; color: #555;\">Under <a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\">ESHO 2014<\/a> annonserte <a href=\"https:\/\/andromedichyperthermia.com\/hyperthermia-doctor-salvatore-conte\/\"><strong>Dr. Salvatore Conte<\/strong><\/a> en stor milep\u00e6l for Andromedics hypertermi-team: vellykket produksjon og levering av 25 <a href=\"https:\/\/andromedichyperthermia.com\/no\/onkologisk-rf-hypertermienhet\/\"><strong>HyDeep 600WM<\/strong>-enheter for dyp lokal hypertermi<\/a> p\u00e5 kun 18 m\u00e5neder, med ytterligere 40 enheter \u00f8remerket India.<\/p>\n<\/header>\n<div style=\"margin-bottom: 50px; border-radius: 15px; overflow: hidden; box-shadow: 0 10px 25px rgba(0,0,0,0.2);\">\n<p><iframe loading=\"lazy\" title=\"intervento Andromedic   Esho 20014\" width=\"640\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/fgMdXxoJ1cI?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<\/div>\n<h2 style=\"text-align: center; color: #1a2a6c; margin-bottom: 30px; text-transform: uppercase;\">Presenterte kliniske studier: HyDeep 600WM avansert onkologisk hypertermi<\/h2>\n<section style=\"margin-bottom: 50px; border: 1px solid #e1e8ed; border-radius: 15px; overflow: hidden; box-shadow: 0 5px 15px rgba(0,0,0,0.05);\">\n<div style=\"background: #1a2a6c; color: #fff; padding: 20px;\">\n<h3 style=\"margin: 0; font-size: 19px;\">1. Kemoradioterapi + hypertermi + HDR-brachyterapi for LACC<\/h3>\n<\/div>\n<div style=\"padding: 30px; background: #f9f9f9;\">\n<p><strong>M\u00c5L:<\/strong> Unders\u00f8ke utfallet av \u00e5 kombinere ukentlig cisplatin og dyp lokal hypertermi med IMRT etterfulgt av BRT for lokalt avansert livmorhalskreft (LACC).<\/p>\n<div style=\"background: #fff; padding: 20px; border-radius: 10px; margin: 20px 0; border-left: 5px solid #b21f1f;\">\n<p><strong>MATERIALER OG METODER:<\/strong><\/p>\n<ul style=\"margin-top: 10px; font-size: 15px;\">\n<li><strong>Pasientgruppe:<\/strong> 8 pasienter (3 stadie IIB, 1 IIIB, 2 NEI, 3 LRCC).<\/li>\n<li><strong>Protokoll:<\/strong> 50,4 Gy til bekkenlymfeknuter med SIB til GTV (61,8 Gy totalt) i 28 fraksjoner. BRT-dose: 21 Gy i 3 fraksjoner.<\/li>\n<li><strong>Samtidig terapi:<\/strong> Ukentlig Cisplatin 40mg\/m\u00b2 + HT \u00e9n gang i uken.<\/li>\n<\/ul>\n<\/div>\n<div style=\"background: #e8f5e9; padding: 20px; border-radius: 10px; border: 1px solid #2e7d32;\">\n<p><strong style=\"color: #1b5e20; font-size: 17px; display: block; margin-bottom: 10px;\">RESULTATER OG KONKLUSJONER:<\/strong><\/p>\n<p style=\"font-size: 16px; font-weight: bold; margin: 0;\">100 % LOKAL KONTROLL OPPN\u00c5DD. Ingen behandlingsrelatert akutt eller sen grad 3 til 4 toksisitet observert.<\/p>\n<p style=\"margin-top: 10px; font-style: italic;\">&laquo;Tillegg av dyp lokal hypertermi til kemoradioterapi representerer en lovende ny strategi med utmerket toleranse.&raquo;<\/p>\n<\/div>\n<\/div>\n<\/section>\n<section style=\"margin-bottom: 50px; border: 1px solid #e1e8ed; border-radius: 15px; overflow: hidden; box-shadow: 0 5px 15px rgba(0,0,0,0.05);\">\n<div style=\"background: #b21f1f; color: #fff; padding: 20px;\">\n<h3 style=\"margin: 0; font-size: 19px;\">2. Mulighetsstudie (case-control) \u2013 dyp lokal hypertermi &#8211; Andalusia, Spania<\/h3>\n<\/div>\n<div style=\"padding: 30px;\">\n<p><strong>Introduksjon:<\/strong> Det f\u00f8rste kliniske fors\u00f8ket i Spania som kombinerer dyp lokal hypertermi med standard kreftbehandlinger innen det offentlige helsevesenet.<\/p>\n<div style=\"display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 20px; margin: 25px 0;\">\n<div style=\"background: #f0f4f8; padding: 15px; border-radius: 10px; border-top: 4px solid #1a2a6c;\"><strong>Studiedesign:<\/strong> Prospektiv case-control-studie. 293 pasienter totalt (97 i aktiv fase vs. 196 kontroller). 9 tumorlokasjoner.<\/div>\n<div style=\"background: #f0f4f8; padding: 15px; border-radius: 10px; border-top: 4px solid #1a2a6c;\"><strong>Behandlingsparametre:<\/strong> 10 \u00f8kter (2-3\/uke), 1 times varighet, 150W\u2013400W ved bruk av <strong>HyDeep 600WM modulert hypertermi-enhet<\/strong>.<\/div>\n<\/div>\n<h4 style=\"color: #1a2a6c; border-bottom: 2px solid #b21f1f; display: inline-block; padding-bottom: 5px;\">Forel\u00f8pige data (undergruppe p\u00e5 22 pasienter):<\/h4>\n<ul style=\"margin-top: 15px; font-size: 14px; column-count: 2;\">\n<li><strong>Glioblastom (2c)<\/strong><\/li>\n<li><strong>Hode og hals (7c)<\/strong><\/li>\n<li><strong>Preoperativ rektum (3c)<\/strong><\/li>\n<li><strong>Brystkreft (3c)<\/strong><\/li>\n<li><strong>Lunge (NSCLC &#8211; 11c)<\/strong><\/li>\n<li><strong>Prostata (4c)<\/strong><\/li>\n<li><strong>Cervix og metastaser<\/strong><\/li>\n<\/ul>\n<div style=\"display: flex; flex-wrap: wrap; gap: 15px; margin: 25px 0;\">\n<div style=\"flex: 1; min-width: 200px; background: #fffde7; padding: 20px; border-radius: 10px; text-align: center; border: 1px solid #fbc02d;\"><span style=\"font-size: 28px; font-weight: 800; display: block;\">81.2%<\/span><br \/>\n<strong>H\u00d8Y TOLERANSE<\/strong><br \/>\n<small>Pasienter tilfredse eller sv\u00e6rt tilfredse<\/small><\/div>\n<div style=\"flex: 1; min-width: 200px; background: #f1f8e9; padding: 20px; border-radius: 10px; text-align: center; border: 1px solid #7cb342;\"><span style=\"font-size: 28px; font-weight: 800; display: block;\">66.6%<\/span><br \/>\n<strong>NULL TOKSISITET<\/strong><br \/>\n<small>Ingen bivirkninger rapportert<\/small><\/div>\n<\/div>\n<p style=\"background: #f4f7f9; padding: 15px; border-radius: 8px; border-left: 4px solid #1a2a6c;\"><strong>KONKLUSJON:<\/strong> Dyp lokal hypertermi er gjennomf\u00f8rbart i rutinemessig offentlig sykehusbehandling uten ekstraordin\u00e6re ressurser. Riktig pasientutvalg sikrer minimal (grad 1) toksisitet.<\/p>\n<div style=\"text-align: center; margin-top: 30px;\"><a style=\"display: inline-block; background: #b21f1f; color: #fff; padding: 14px 30px; text-decoration: none; border-radius: 5px; font-weight: 800; text-transform: uppercase; box-shadow: 0 4px 10px rgba(178,31,31,0.3);\" href=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Protocolo-del-ensayo-MAG-HIP-2013-01-11-EN.pdf\">Last ned fullstendig studieprotokoll (PDF)<\/a><\/div>\n<\/div>\n<\/section>\n<div style=\"margin-top: 40px;\">\n<h3 style=\"text-align: center; color: #1a2a6c; text-transform: uppercase; letter-spacing: 1px;\">ESHO vitenskapelige postere og dokumentasjon<\/h3>\n<div id='gallery-1' class='gallery galleryid-3998 gallery-columns-1 gallery-size-full'><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon portrait'>\n\t\t\t\t<a href=\"https:\/\/andromedichyperthermia.com\/no\/preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma-2\/\"><img loading=\"lazy\" decoding=\"async\" width=\"590\" height=\"837\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma.jpg\" class=\"attachment-full size-full\" alt=\"\" aria-describedby=\"gallery-1-1336\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma.jpg 590w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma-211x300.jpg 211w\" sizes=\"auto, (max-width: 590px) 100vw, 590px\" title=\"\"><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-1336'>\n\t\t\t\tPreliminary results of chemoradiation plus Andromedic hyperthermia and high dose rate brachytherapy for locally advanced cervical carcinoma\n\t\t\t\t<\/figcaption><\/figure><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon portrait'>\n\t\t\t\t<a href=\"https:\/\/andromedichyperthermia.com\/no\/quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-b-2\/\"><img loading=\"lazy\" decoding=\"async\" width=\"569\" height=\"831\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-B.jpg\" class=\"attachment-full size-full\" alt=\"\" aria-describedby=\"gallery-1-1315\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-B.jpg 569w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-B-205x300.jpg 205w\" sizes=\"auto, (max-width: 569px) 100vw, 569px\" title=\"\"><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-1315'>\n\t\t\t\tQuasi feasibility study(case control) asscoaiting deep local hyperthermia treatment with standard cancer treatments and describing patterns of response ESHO\n\t\t\t\t<\/figcaption><\/figure><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon portrait'>\n\t\t\t\t<a href=\"https:\/\/andromedichyperthermia.com\/no\/quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-2\/\"><img loading=\"lazy\" decoding=\"async\" width=\"568\" height=\"826\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg\" class=\"attachment-full size-full\" alt=\"\" aria-describedby=\"gallery-1-1294\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg 568w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-206x300.jpg 206w\" sizes=\"auto, (max-width: 568px) 100vw, 568px\" title=\"\"><\/a>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-1294'>\n\t\t\t\tQuasi feasibility study(case control) asscoaiting deep local hyperthermia HyDeep 600WM treatment with standard cancer treatments and describing patterns of response\n\t\t\t\t<\/figcaption><\/figure>\n\t\t<\/div>\n\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>European Society for Hyperthermic Oncology: ESHO 2014 Andromedic-intervensjon \u2013 Dr. Salvatore Conte Under ESHO 2014 annonserte Dr. Salvatore Conte en stor milep\u00e6l for Andromedics hypertermi-team: vellykket produksjon og levering av 25 HyDeep 600WM-enheter for dyp lokal hypertermi p\u00e5 kun 18 m\u00e5neder, med ytterligere 40 enheter \u00f8remerket India. Presenterte kliniske studier: HyDeep 600WM avansert onkologisk hypertermi&hellip;<\/p>\n","protected":false},"author":1,"featured_media":17348,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-gutentor-full-width.php","meta":{"footnotes":""},"class_list":["post-3998","page","type-page","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/no\/wp-json\/wp\/v2\/pages\/3998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/no\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/no\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/no\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/no\/wp-json\/wp\/v2\/comments?post=3998"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/no\/wp-json\/wp\/v2\/pages\/3998\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/no\/wp-json\/wp\/v2\/media\/17348"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/no\/wp-json\/wp\/v2\/media?parent=3998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}